U.S. Lyophilization Services for Biopharmaceuticals Market to Reach USD 814.6 Million in 2024 with a 9.8% CAGR Through 2034

The U.S. Lyophilization Services for Biopharmaceuticals Market was valued at US$ 814.6 million in 2024 and is projected to grow at a CAGR of around 9.8% through 2034. Expanding biologics pipelines, rising commercialization of monoclonal antibodies, advanced vaccines, and mRNA-based therapeutics are driving strong demand for high-precision freeze-drying capabilities across the country.

The market holds a strong and expanding position within the U.S. biopharmaceutical manufacturing ecosystem. Growing reliance on contract development and manufacturing organizations (CDMOs), advancements in automated lyophilization systems, and increasing focus on product stability, shelf-life extension, and global distribution efficiency are reinforcing the sector's momentum. With biologics continuing to dominate therapeutic innovation, lyophilization services remain a mission-critical component of U.S. drug development and commercialization.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/lyophilization-services-for-biopharmaceuticals-market?sai-v

The lyophilization services for the biopharmaceuticals market involve specialized freeze-drying services that help stabilize and preserve biologic drugs, vaccines, and proteins, extending shelf life and ensuring effectiveness during storage and transport.

Key Developments

United States

✅ September 2025: The global lyophilization services market is projected to nearly double by 2035, driven by demand for stabilized biologics and adoption of automated and continuous freeze-drying systems.

✅ 2025: There is growing demand for customized lyophilization cycles and primary packaging options, especially as biopharma companies increasingly outsource to CDMOs for their lyophilization needs.

✅ 2025: Contract development and manufacturing organizations (CDMOs) are investing in scaling up their lyophilization capacity to serve a growing biotherapeutics pipeline.

Japan

✅ March 2025: Japanese biopharma companies are seeking more outsourced lyophilization services to support formulation development of novel biologics, as building in-house freeze-drying capacity remains capital-intensive.

✅ 2025: There is increased interest among Japanese CMOs in offering integrated lyophilization and fill-finish services for vaccines and mAbs, to better serve local and global biologics manufacturers.

Mergers & Strategic Moves

United States

✅ May 2025: Ajinomoto Co. sold its entire stake in Ajinomoto Althea (a U.S.-based fill-finish CDMO that provided lyophilization services) to Packaging Coordinators, consolidating lyophilization capacity under a new CDMO.

Key Players:
ATTWILL Medical Solutions | Axcellerate Pharma LLC | AB BioTechnologies, Inc. | Berkshire Sterile Manufacturing, Inc. | Emergent BioSolutions | LSNE Contract Manufacturing | Lyophilization Technology, Inc. | Jubilant HollisterStier LLC | Biofortuna Ltd | GILYOS GmbH

Key Highlights:
• ATTWILL Medical Solutions - A leading U.S.-based CDMO specializing in aseptic manufacturing, lyophilization, and sterile fill-finish services, supporting large-scale pharmaceutical and biologics production for clinical and commercial needs.

• Axcellerate Pharma LLC - A major sterile injectables and lyophilization service provider offering end-to-end CDMO capabilities including formulation, fill-finish, and controlled storage for biologics and high-value therapeutics.

• AB BioTechnologies, Inc. - Recognized for expertise in formulation development, cycle design, and small-batch lyophilization services for vaccines, biologics, and diagnostic products under GMP conditions.

• Berkshire Sterile Manufacturing, Inc. - A leading U.S.-based sterile CDMO known for isolator-based aseptic processing and advanced lyophilization technologies serving both biotech and pharmaceutical clients.

• Emergent BioSolutions - A global biopharmaceutical company with strong capabilities in sterile manufacturing, vaccine production, and emergency medical countermeasures; contributes to multi-billion-dollar annual corporate revenue.

• LSNE Contract Manufacturing (a PCI Pharma Services company) - A major CDMO offering comprehensive lyophilization, sterile fill-finish, and biologics manufacturing services across multiple GMP facilities globally.

• Lyophilization Technology, Inc. (LTI) - A specialty provider focused on lyophilization process development, optimization, and technology transfer for injectable and biologic drug products.

• Jubilant HollisterStier LLC - A leading contract manufacturer delivering sterile injectables, lyophilization, and aseptic filling solutions; contributing significantly to Jubilant Pharma's global pharmaceutical services revenue.

• Biofortuna Ltd - A UK-based specialist in lyophilized diagnostics, molecular assays, and custom manufacturing, supporting large-scale freeze-dried assay production for global diagnostics companies.

• GILYOS GmbH - A German contract research and development organization focused on lyophilization science, offering advanced freeze-drying formulation, analytics, and process consultancy for pharma and biotech clients.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=lyophilization-services-for-biopharmaceuticals-market?sai-v

Market Drivers & Growth

- Rising biologics and biologic drug development: Increased production of monoclonal antibodies, vaccines, and cell & gene therapies is driving demand for freeze-drying to enhance stability and shelf life.

- Growing outsourcing trend: Biopharma companies are increasingly outsourcing lyophilization to specialized CDMOs to reduce costs and access advanced infrastructure.

- Increasing need for temperature-sensitive formulations: Lyophilization enables safe storage and transport of fragile biopharmaceuticals, supporting market growth.

- Expansion of injectable therapeutics: Growth in parenteral drug formulations is boosting adoption of freeze-drying technologies.

- Technological innovation: Advances in lyophilizers, PAT tools, automated loading-unloading systems, and cycle optimization are enhancing efficiency and scalability.

Industrial Advances & Developments

- Automated freeze-drying systems: Adoption of robotics and smart monitoring tools to reduce human error and improve process control.

- Continuous lyophilization technologies: Development of next-generation continuous systems to reduce cycle times significantly.

- Improved cycle development software: Use of advanced modeling, AI-based prediction tools, and design of experiments (DoE) to optimize drying cycles.

- Expansion of CDMO capacities: Leading service providers are increasing GMP lyophilization capacity with new facilities and large-scale lyophilizers.

- Integration with single-use technologies: Growing use of disposable systems for aseptic transfers and contamination prevention.

Regional Insights

- North America: Largest market with strong presence of biopharma companies, CDMOs, and advanced freeze-drying facilities.

- Europe: Significant adoption driven by a robust biologics pipeline, regulatory compliance, and well-established pharmaceutical manufacturing.

- Asia-Pacific: Fastest-growing region due to expanding biomanufacturing, investment in biologics, and rising outsourcing to India, China, and South Korea.

- Latin America & Middle East: Gradual growth supported by increasing pharmaceutical production and import dependencies for biologic drugs.

Key segments

➥ By Service Type
Product & Cycle Development leads as companies increasingly outsource R&D and process optimization to accelerate time-to-market. Clinical and Commercial Manufacturing services grow steadily with rising biologics and vaccine production. Freeze Drying & Analytical Services expand due to demand for stable, long-shelf-life formulations.

➥ By Application
Vaccines and Antibodies dominate the market driven by rising infection control needs and biologics development. Antibiotics remain essential for large-scale therapeutic production, while Vitamins and Hormones see consistent demand in preventive and specialty healthcare.

➥ By End-User
Pharmaceutical & Biotechnology Companies account for the largest share as they rely heavily on outsourcing to reduce operational burden. Research Institutes contribute steadily through continuous innovation and clinical research activities, while Others include emerging biotech startups and specialty manufacturers.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/lyophilization-services-for-biopharmaceuticals-market?sai-v

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.